Compounded vs. Brand GLP-1s: The Complete Guide
Brand-name Wegovy costs ~$1,350/month. Compounded semaglutide can cost as little as $200/month. The price gap created one of the largest gray markets in pharmaceutical history — and now the FDA is cracking down. Here's everything you need to know.
The Core Trade-Off at a Glance
Brand-Name GLP-1s
- ✅ FDA-approved, clinical trial data
- ✅ Standardized purity and dosing
- ✅ Manufacturer safety monitoring
- ❌ ~$1,000–1,500/month without insurance
- ❌ Frequent supply shortages historically
Compounded GLP-1s
- ✅ ~$200–400/month significantly cheaper
- ✅ Wider telehealth access
- ❌ Not FDA-approved, no clinical trials
- ❌ Quality and purity varies by pharmacy
- ❌ Legal status changing rapidly
Table of Contents
What Are Compounded GLP-1s?
Compounded GLP-1s are copies of brand-name medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) made by compounding pharmacies rather than the original manufacturers.
Compounding is a legal pharmaceutical practice where pharmacists combine, mix, or alter ingredients to create customized medications. It has long been used to:
- Create medications not commercially available (e.g., a pediatric liquid form of an adult pill)
- Remove allergens (dyes, preservatives) for sensitive patients
- Adjust doses that aren't available in standard commercial forms
- Fill supply gaps during FDA-declared drug shortages
The GLP-1 compounding boom happened primarily because of the third reason: the FDA declared both semaglutide and tirzepatide in shortage status, which under federal law allows compounding pharmacies to legally produce copies of those medications.
- 503A pharmacies — Traditional pharmacies that compound on a prescription-by-prescription basis. Less oversight, but legal for individual patients.
- 503B outsourcing facilities — Larger-scale facilities registered with the FDA, subject to cGMP inspections. Higher quality standards, but not FDA approval for specific products.
FDA's Position on Compounded GLP-1s
The FDA's stance on compounded GLP-1s has shifted dramatically and continues to evolve. Understanding this timeline is essential:
GLP-1 shortage declarations
The FDA placed semaglutide and tirzepatide on the drug shortage list as demand far exceeded supply. This legally enabled compounding pharmacies to produce copies.
Compounding market explodes
Thousands of compounding pharmacies — and telehealth platforms like Hims, Ro, and Found — began offering compounded semaglutide and tirzepatide at dramatically lower prices.
FDA resolves semaglutide shortage
The FDA removed semaglutide from its shortage list, triggering enforcement actions. The agency issued cease-and-desist letters to compounders and set compliance deadlines for 503B facilities.
Ongoing legal battles and crackdown
Several compounding pharmacies and telehealth companies challenged FDA's actions in court. Tirzepatide remains in a more complex legal situation, with some formulations still on the shortage list.
Current FDA stance (2026):
The FDA considers compounded semaglutide unlawful now that the shortage has been resolved. Compounded tirzepatide exists in a more ambiguous legal space. Any compounded GLP-1 you access today carries legal and quality risk that did not exist in 2023–2024.
Brand Names vs. Compounded: What's Actually Different?
At the molecular level, compounders aim to use the same active ingredient. The differences lie in everything around the molecule:
| Brand-Name | Compounded | |
|---|---|---|
| FDA approval | ✅ Yes — full NDA | ❌ No |
| Clinical trial data | ✅ Phase 2/3 trials | ❌ None on formulation |
| Purity verification | ✅ Standardized batch testing | ⚠ Varies by pharmacy |
| Inactive ingredients | Standardized, FDA-reviewed | May differ — no review |
| Dosing accuracy | Pen-auto-measured | Often drawn by syringe; error risk |
| Adverse event reporting | Mandatory pharmacovigilance | Voluntary, inconsistent |
| Examples | Wegovy, Ozempic (sema); Zepbound, Mounjaro (tirz) | Compounded semaglutide/tirzepatide vials |
One key practical difference: brand-name GLP-1s come in pre-filled auto-injector pens where the dose is set by the manufacturer. Compounded versions typically come in multi-dose vials that patients draw into syringes — introducing more potential for dosing errors.
Additionally, some compounders have added additives like B12 or other compounds to their formulations. These are not present in the FDA-approved products and have not been studied for safety or interaction effects.
Cost Comparison
The cost gap is the central reason compounded GLP-1s became so popular. Here's how the numbers break down:
| Option | Monthly Cost | Notes |
|---|---|---|
| Wegovy (2.4 mg brand) | ~$1,349 | List price; insurance may cover |
| Wegovy HD (7.2 mg brand) | ~$1,500+ | Newly approved March 2026 |
| Ozempic (off-label weight loss) | ~$935 | Diabetes-approved; often not covered for weight loss |
| Zepbound (tirzepatide brand) | ~$1,059 | Eli Lilly's weight loss formulation |
| Compounded semaglutide | $200–$400 | Telehealth platforms; 503A/503B |
| Compounded tirzepatide | $250–$500 | More widely available in 2026 than sema |
Insurance and savings options for brand-name GLP-1s:
- Many commercial insurance plans now cover Wegovy for obesity (BMI ≥30 or ≥27 with comorbidities)
- Novo Nordisk and Eli Lilly both offer patient savings programs — check manufacturer websites
- The TrumpRx initiative announced in 2025 aims to reduce prices through manufacturer agreements
- GoodRx and discount cards can reduce costs significantly at some pharmacies
For uninsured patients, the compounded price advantage is hard to ignore. A year of brand-name Wegovy can cost over $16,000 out-of-pocket versus $2,400–4,800 for compounded alternatives.
Safety & Quality Concerns
Safety concerns with compounded GLP-1s are real and documented. They don't mean compounded versions are universally dangerous — but they mean the risk calculus is meaningfully different.
Documented Safety Issues
- Adverse event reports: The FDA received hundreds of adverse event reports related to compounded semaglutide, including hospitalizations — some linked to incorrect concentrations
- Purity variation: Third-party testing of compounded semaglutide samples has found inconsistent active ingredient concentrations across batches and suppliers
- Impurities: Some samples have been found to contain semaglutide sodium instead of semaglutide acetate, which may have different pharmacological properties
- Unapproved additives: Many compounders add B12, L-carnitine, or other compounds not present in FDA-approved formulations and not studied for safety in combination
How to Reduce Risk If You Choose Compounded
- Use an FDA-registered 503B outsourcing facility rather than a smaller 503A pharmacy — higher manufacturing standards
- Request a Certificate of Analysis (CoA) showing third-party purity testing for your specific batch
- Work with a licensed prescriber who can monitor your response and any side effects
- Avoid formulations with unapproved additives (B12, L-carnitine, etc.) unless clinically indicated
Legal Landscape
The legality of compounded GLP-1s is not a settled question — it varies by drug, timing, and geography, and is actively contested in courts.
Federal Law Framework
Under the Food, Drug & Cosmetic Act, compounding is generally permissible when a drug is on the FDA's shortage list. When a shortage is resolved, the basis for bulk compounding disappears. The FDA can then pursue enforcement actions against pharmacies continuing to produce the drug at scale.
Semaglutide (2026 status)
- ⚠Removed from FDA shortage list in early 2025
- ⚠FDA issued enforcement discretion deadlines for 503A and 503B compounders
- ⚠Several large compounders filed lawsuits challenging FDA authority — outcomes vary by circuit
- ⚠Small 503A pharmacies may still compound for individual prescriptions in some states
Tirzepatide (2026 status)
- ✅Remains on the FDA shortage list in some formulations as of 2026
- ✅Compounded tirzepatide is more widely available and legally defensible than compounded semaglutide
- ⚠This could change quickly if FDA resolves the tirzepatide shortage
State-Level Variation
Compounding is also regulated at the state level by boards of pharmacy. Some states have stricter oversight than federal minimums; others are more permissive. A compounding pharmacy legal in one state may not meet standards in another. Always verify that any pharmacy you use is licensed in your state.
Telehealth Access: How People Get Compounded GLP-1s
The typical pathway for compounded GLP-1s runs through telehealth platforms that partner with compounding pharmacies. These platforms made compounded semaglutide and tirzepatide widely accessible:
Hims & Hers
One of the largest telehealth platforms offering compounded GLP-1s. Faced significant legal challenges when FDA moved against compounders in 2025.
Ro (Roman)
Launched a compounded semaglutide program that grew rapidly. Has adjusted offerings as regulatory landscape has evolved.
Found
Focuses on medically supervised weight management, offering both compounded and, where available, brand-name options.
Henry Meds
Telehealth platform focused on metabolic health, including GLP-1 prescriptions through partnered pharmacies.
LifeMD / Trtl Health
Broader telehealth platforms with weight management tracks that have offered compounded GLP-1s.
Who Should Consider Each Option?
Brand-Name GLP-1s Are Likely Better If:
- You have insurance coverage that brings the cost down significantly
- You want FDA-reviewed quality assurance and standardized dosing
- You have cardiovascular disease — clinical trial benefit data applies to brand formulations
- You value the auto-injector pen device over drawing from a vial
- You prefer maximum legal clarity about your medication source
- You're working with a traditional physician or endocrinologist
Compounded GLP-1s Are Sometimes Considered When:
- You have no insurance coverage and brand prices are genuinely unaffordable
- You've been waiting months for brand-name supply to become available
- You're accessing a tirzepatide compound while shortage status still permits it
- You use a reputable 503B facility and can obtain Certificate of Analysis
- You're being monitored by a licensed provider who can adjust dosing
- You understand and accept the quality and legal risks involved
The Emerging Option: Oral GLP-1s
Two developments are creating new alternatives to the brand-vs-compounded binary:
- Oral semaglutide (Rybelsus): FDA-approved for weight management as of January 2026 — an injectable-free brand-name option, though typically more expensive than compounded injections
- Orforglipron (Foundayo):The first oral small-molecule GLP-1 agonist. Unlike peptide-based GLP-1s, it cannot be compounded — it's a synthetic small molecule. FDA-approved in 2026. See our orforglipron guide for details
Frequently Asked Questions
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved. The active ingredient (semaglutide) is FDA-approved in brand-name products like Wegovy and Ozempic, but compounded versions have not undergone FDA review for safety, efficacy, or manufacturing quality.
Why is compounded semaglutide so much cheaper?
Compounding pharmacies do not conduct clinical trials, seek FDA approval, or pay for branded marketing. They manufacture from bulk active pharmaceutical ingredients. Brand prices reflect R&D investment, clinical trial costs, and patent-protected status.
Is compounded semaglutide safe?
Quality varies widely. Compounded versions from FDA-registered 503B outsourcing facilities have stricter quality standards than standard 503A pharmacies. There are no published clinical trials on compounded semaglutide formulations, and the FDA has received adverse event reports, including from patients who received incorrect concentrations.
Can I still get compounded semaglutide in 2026?
The FDA removed semaglutide from its shortage list in early 2025, triggering a crackdown on compounders. As of 2026, compounding of semaglutide is largely restricted except in limited circumstances. Tirzepatide remains on the shortage list in some formulations, so compounded tirzepatide is more widely available.
What is a 503B pharmacy?
503B outsourcing facilities are large-scale compounding pharmacies registered with the FDA. They must comply with Current Good Manufacturing Practices (cGMP), undergo FDA inspections, and provide sterility and quality testing. They represent the higher-quality end of the compounding spectrum.
Does compounded semaglutide work as well as Wegovy?
Theoretically yes, if the formulation is identical. But there is no clinical trial data on compounded formulations specifically. The inactive ingredients, concentration accuracy, and formulation can all affect absorption and tolerability. Most patients report similar effects, but the evidence base supporting brand-name products does not formally extend to compounded versions.
What should I ask a compounding pharmacy before ordering?
Ask: (1) Are you a 503A or 503B facility? (2) Can you provide a Certificate of Analysis (CoA) for the specific batch? (3) What testing do you use for purity and concentration? (4) Is semaglutide acetate used (not sodium)? (5) Are any additives included and why? (6) Are you licensed in my state?
Sources
- 1.FDA. "FDA Updates on GLP-1 Drug Shortages." FDA.gov. Various updates 2023–2026.
- 2.FDA. "Compounding and the FDA: Questions and Answers." FDA.gov.
- 3.FDA. "FDA Takes Action Against Compounding of Semaglutide." MedWatch Safety Alerts, 2025.
- 4.Alliance for Pharmacy Compounding. "503A vs 503B Pharmacies: Key Differences." APC, 2024.
- 5.Novo Nordisk. "Wegovy (semaglutide) Prescribing Information." 2024.
- 6.Eli Lilly. "Zepbound (tirzepatide) Prescribing Information." 2024.
- 7.JAMA Internal Medicine. "Analysis of Compounded GLP-1 Receptor Agonists and Adverse Events." 2025.
- 8.FDA MedWatch. Adverse event reports related to compounded semaglutide products. 2024–2025.